This signature is sensitive (responds to both genetic and pharmacological perturbation) and specific for BACH1 (does not respond to NRF2 modulation) and can be used to provide further insight into the pro-metastatic role of BACH1 in lung cancer cells and as a tool to identify new BACH1 inhibitors. Here, NFE2L2 is linked to lung cancer.